GlassScriptPhysician profile
Karyl Nicole Hobbs
NPI 1457696080
$4,564.92
in general payments reported to CMS, 2019-2025
37 companies · $835 in 2025
The $835 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,850 · 2022: $117 · 2023: $775 · 2024: $987 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,597.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $571.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $536.47 | 2021-2025 | Farxiga, Airsupra |
| Exact Sciences Corporation | $404.28 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $317.10 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $219.83 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.11 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $173.99 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $167.83 | 2021-2025 | |
| Endo USA, INC. | $158.17 | 2024-2025 | Xiaflex, Edex, Aveed |
| Amarin Pharma, INC. | $145.78 | 2021 | |
| Merck Sharp & Dohme LLC | $141.13 | 2021-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Pfizer INC. | $137.59 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $135.33 | 2021 | |
| Esperion Therapeutics, INC. | $134.66 | 2021 | |
| Dexcom, INC. | $128.55 | 2021-2025 | Dexcom G6 Transmitter |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $95.82 | 2021 | |
| Myriad Genetic Laboratories, INC. | $85.62 | 2023-2024 | Myrisk, Prolaris |
| Procept Biorobotics Corporation | $83.50 | 2025 | |
| Novartis Pharmaceuticals Corporation | $76.51 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $72.26 | 2021 | |
| Janssen Biotech, INC. | $71.98 | 2025 | Erleada |
| Paratek Pharmaceuticals, INC. | $71.66 | 2021 | |
| Axonics, INC. | $70.45 | 2022-2023 | Axonics |
| Abbott Laboratories | $58.69 | 2021-2023 | Freestyle Libre 2 |
| Endo Pharmaceuticals INC. | $49.77 | 2023 | Xiaflex |
| Antares Pharma, INC. | $42.17 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $36.41 | 2021 | |
| Nevro Corp. | $34.20 | 2024 | Senza |
| Sumitomo Pharma America, INC. | $25.98 | 2023 | Gemtesa |
| Boston Scientific Corporation | $22.52 | 2023 | Rezum Generator |
| Photocure INC | $21.32 | 2024 | Cysview |
| 180 Medical, INC. | $18.50 | 2024 | |
| Medtronic, INC. | $17.78 | 2021 | |
| Eisai INC. | $15.87 | 2021 | |
| Urovant Sciences INC | $14.95 | 2022 | |
| Si-Bone, INC. | $14.82 | 2024 | |
| Arbor Pharmaceuticals, INC. | $13.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karyl Hobbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.